Adaptive Biotechnologies (ADPT) still was trading more than 6% higher late in Friday's session, roughly halving its earlier advance after analysts at Goldman Sach raised their stock rating for the immuno-sequencing company to buy from neutral previously.
The Goldman analysts also increased their price target for Adaptive shares to $9 from their prior call of $8 per share.
Price: 8.24, Change: +0.48, Percent Change: +6.26
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.